1-[(6-Chloropyridin-3-yl)methyl]-4-(pyridin-2-yl)piperazine

Catalog No. :
ACSMVO250
CAS No. :
861211-54-3
Molecular Formula :
C15H17ClN4
Molecular Weight :
288.78

IUPAC Name:1-((6-chloropyridin-3-yl)methyl)-4-(pyridin-2-yl)piperazine

1-[(6-Chloropyridin-3-yl)methyl]-4-(pyridin-2-yl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg95%$121.00Login to see priceInquiryInquiry
10mg95%$148.00Login to see priceInquiryInquiry
50mg95%$208.00Login to see priceInquiryInquiry
100mg95%$274.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-[(6-Chloropyridin-3-yl)methyl]-4-(pyridin-2-yl)piperazine
IUPAC Name1-((6-chloropyridin-3-yl)methyl)-4-(pyridin-2-yl)piperazine
MDL No.MFCD04125023
Molecular FormulaC15H17ClN4
Molecular Weight288.78
SMILESClC1=CC=C(CN2CCN(C3=NC=CC=C3)CC2)C=N1
InChI KeyIWMSXWCTNJUYHZ-UHFFFAOYSA-N
SynonymPiperazine, 1-[(6-chloro-3-pyridinyl)methyl]-4-(2-pyridinyl)-
CAS No.861211-54-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACSMVO250 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUGEK285 route compound structure diagram
    ACUGEK28534803-66-2 In Stock
  4. Then
  5. ACSMVO250 route product structure diagram
    ACSMVO250861211-54-3
Inquiry

2. ACSMVO250 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCTJM471 route compound structure diagram
    ACCTJM47123100-12-1 In Stock
  2. Plus
  3. ACUGEK285 route compound structure diagram
    ACUGEK28534803-66-2 In Stock
  4. Then
  5. ACSMVO250 route product structure diagram
    ACSMVO250861211-54-3
Inquiry

Comments (0)